A new discovery related to the mechanism of the danger signal adenosine triphosphate could influence how immunomodulators, such as vaccines and allergy medications, are formulated.
Regeneron and partner Alnylam have developed a siRNA therapeutic candidate targeting CIDEB gene that the companies anticipate will enter the clinic within the next year.
Pfizer and Flynn Pharma are under the scrutiny of British watchdogs once again, after officials said the companies have been overcharging for an anti-epilepsy medication in the U.K. for over four years.
Physicians at New York University have successfully implanted pig hearts into the bodies of patients that were living but no longer showed neural function, a process called xenotransplantation.
Tonix Pharmaceuticals announced a mid-stage study for major depressive disorder, which followed the June disclosure of a Phase II study for a cocaine intoxication therapy.
Seagen announced positive data from its Phase II trial in colorectal cancer, and the FDA provided positive feedback supporting a Phase IIIb trial for ANeuroTech’s MDD drug.
A deadly fungus–Candida auris (C. auris)–has shaken up the biological world with its ability to reproduce sexually. What can be its dangers and what are the next steps? Know it all here.
The Boston University School of Medicine has unraveled details about a known genetic component for the development of Alzheimer’s disease (AD): the APOE4 gene.
Researchers at Imperial College London have developed a novel diagnosis method with a high rate of correct Alzheimer’s diagnosis and the ability to determine the patient’s progression stage.
GSK’s MMR vaccine is only the second to be approved in the United States for protection against measles, mumps and rubella. The first, licensed to Merck, was approved in 1971.
Amylyx Pharmaceuticals shared news that the FDA has extended the review period for AMX0035, a combination drug treatment with the potential to treat patients with ALS.
